Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1996-05

AUTHORS

Brian J. Druker, Shu Tamura, Elisabeth Buchdunger, Sayuri Ohno, Gerald M. Segal, Shane Fanning, Jürg Zimmermann, Nicholas B. Lydon

ABSTRACT

The bcr–abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr–Abl fusion protein. Cellular proliferation and tumor formation by Bcr–Abl–expressing cells were specifically inhibited by this compound. In colony–forming assays of peripheral blood or bone marrow from patients with CML, there was a 92–98% decrease in the number of bcr–abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr–abl–positive leukemias. More... »

PAGES

561-566

Journal

TITLE

Nature Medicine

ISSUE

5

VOLUME

2

Related Patents

  • Uses Of Diazepane Derivatives
  • Mutations In The Bcr-Abl Tyrosine Kinase Associated With Resistance To Sti-571
  • Compositions And Methods For Treating Leukemia
  • Male Contraceptive Compositions And Methods Of Use
  • Episomal Fusion Gene
  • Compounds And Method Of Identifying, Synthesizing, Optimizing And Profiling Protein Modulators
  • Design, Synthesis And Evaluation Of Procaspase Activating Compounds As Personalized Anti-Cancer Drugs
  • Design, Synthesis And Evaluation Of Procaspase Activating Compounds As Personalized Anti-Cancer Drugs
  • Treatment Of Restenosis And Stenosis With Dasatinib
  • Substituted Quinoxalines And Uses Thereof
  • Compounds And Methods For The Treatment Of Cancer
  • Using Erastin As Therapeutic Agent In Treatment Of Cell Proliferative Disorders Associated With Mutation In Ras Gene
  • Therapeutic Targeting Of Myeloproliferative Neoplasms By Dusp1 Inhibition
  • Diazepane Derivatives And Uses Thereof
  • Compounds And Method Of Identifying, Synthesizing, Optimizing And Profiling Protein Modulators
  • Mutations In The Bcr-Abl Tyrosine Kinase Associated With Resistance To Sti-571
  • Design, Synthesis And Evaluation Of Procaspase Activating Compounds As Personalized Anti-Cancer Drugs
  • Prodrug Anti-Cancer Therapy
  • Theramutein Modulators
  • Thienotriazolodiazepine Compounds For Treating Neoplasia
  • 4-Diethylamino-N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-(Trifluoromethyl)-Benzamide; Disease Which Responds To An Inhibition Of Protein Kinase Activity, Especially A Neoplastic Disease; Leukemia
  • Substituted Quinoxalines As Kinase Inhibitors
  • Acetamide Thienotriazolodiazepines And Uses Thereof
  • Male Contraceptive Compositions And Methods Of Use
  • Combination Of Pyrimidylaminobenzamide Compounds And Imatinib For Treating Or Preventing Proliferative Diseases
  • Method To Identify Cancer Fusion Genes
  • Cyano Thienotriazolodiazepines And Uses Thereof
  • Therapy For Kinase-Dependent Malignancies
  • Theramutein Modulators
  • Mutations In The Bcr-Abl Tyrosine Kinase Associated With Resistance To Sti-571
  • Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders
  • Compounds And Methods Of Identifying, Synthesizing, Optimizing And Profiling Protein Modulators
  • Theramutein Modulators
  • Such As The Abl Tyrosine Kinase Domain; Leukemia
  • Administering A Mixture Of 4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]-N-[5-(4-Methyl-1h-Imidazol-1-Yl)-3-(Trifluoromethyl)Phenyl]Benzamide And 4-(4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3-(4-Pyridin-3-Yl)Pyrimidin-2-Ylamino)Phenyl]-Benzamide; Combination Therapy; Antitumor Agents
  • Peptide Inhibitors Of Abl Kinases
  • Quinoxaline Derivatives As Antitumor Agents
  • Diaminopyrimidine Benzenesulfone Derivatives And Uses Thereof
  • Compounds And Methods Of Identifying, Synthesizing, Optimizing And Profiling Protein Modulators
  • Compounds For Modulating T-Cells
  • Compositions And Methods Including Cell Death Inducers And Procaspase Activation
  • Cyclic Protein Tyrosine Kinase Inhibitors
  • Peptide Inhibitors Of Bcr-Abl Oligomerization
  • Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders
  • Pyrrolo-Pyridine Kinase Modulators
  • Cyclic Protein Tyrosine Kinase Inhibitors
  • Pyrrolo-Pyridine Kinase Modulators
  • Cyclic Protein Tyrosine Kinase Inhibitors
  • Nup214-Abl1 Fusion Product, Important In The Development Of T-Cell Acute Lymphoblastic Leukemia; Methods To Detect The Fusion And Prevention Of The Oncogenic Activity Of The Fusion Product
  • Dihydropteridinone Derivatives And Uses Thereof
  • Zebrafish Animal Models For Clarifying Gene Function Relationships In Hyperproliferative Disorders; Antisense Agents; Rna Interference And Tumor Treatment Therapies
  • Procaspase Activating Compounds
  • Modulators Of Gtpase And Use In Relevant Treatment
  • Compounds And Method Of Identifying, Synthesizing, Optimizing And Profiling Protein Modulators
  • Theramutein Modulators
  • Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders
  • Detection Of Gleevec Resistance
  • Diaminopyrimidine Benzenesulfone Derivatives And Uses Thereof
  • Compositions And Methods Relating To Fusion Protein Biomarkers
  • Compositions And Methods Including Cell Death Inducers And Procaspase Activation
  • Theramutein Modulators
  • Determining Polypeptide Sequence Of At Least One Bcr-Abl Polypeptide Expressed By The Human Cancer Cell And Comparing The Polypeptide Sequence Of The Bcr-Abl Polypeptide Expressed By The Human Cancer Cell To The Bcr-Abl Polypeptide Sequence
  • Bivalent Bromodomain Inhibitors And Uses Thereof
  • Inhibitors Of Transcription Factors And Uses Thereof
  • Identification Of Genotype-Selective Anti-Tumor Agents
  • Combination Therapy Of Transcription Inhibitors And Kinase Inhibitors
  • Prodrug Anti-Cancer Therapy
  • Mutations In The Bcr-Abl Tyrosine Kinase Associated With Resistance To St1-571
  • Detection Of Gleevec Resistant Mutations
  • Mutations In The Bcr-Abl Tyrosine Kinase Associated With Resistance To Sti-571
  • Blocking Or Activation Of Endogenous Proteins Variations Rncoded By Mutated Gees
  • Erastin And Erastin Binding Proteins, And Uses Thereof
  • Diagnostic And Prognostic Assays Based On Circulating Tyrosine Kinase Activity
  • Diagnostic Substance, That Reacts With Molecules Which Appear In A Transformed And/Or Infected Biological Cell; Tumor Disease Or/And An Infectious Disease
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/nm0596-561

    DOI

    http://dx.doi.org/10.1038/nm0596-561

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1051513257

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/8616716


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Cardiorespiratory Medicine and Haematology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Benzamides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Blood Cells", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Bone Marrow", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dose-Response Relationship, Drug", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Enzyme Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Evaluation Studies as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Fusion Proteins, bcr-abl", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Imatinib Mesylate", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Piperazines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein-Tyrosine Kinases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proto-Oncogene Proteins c-abl", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pyrimidines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Stem Cells", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Cells, Cultured", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA", 
              "id": "http://www.grid.ac/institutes/grid.5288.7", 
              "name": [
                "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Druker", 
            "givenName": "Brian J.", 
            "id": "sg:person.012015172137.23", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012015172137.23"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA", 
              "id": "http://www.grid.ac/institutes/grid.5288.7", 
              "name": [
                "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tamura", 
            "givenName": "Shu", 
            "id": "sg:person.0603442270.75", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603442270.75"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.419481.1", 
              "name": [
                "Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Buchdunger", 
            "givenName": "Elisabeth", 
            "id": "sg:person.01060303730.59", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060303730.59"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA", 
              "id": "http://www.grid.ac/institutes/grid.5288.7", 
              "name": [
                "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ohno", 
            "givenName": "Sayuri", 
            "id": "sg:person.0717670670.09", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717670670.09"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA", 
              "id": "http://www.grid.ac/institutes/grid.5288.7", 
              "name": [
                "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Segal", 
            "givenName": "Gerald M.", 
            "id": "sg:person.01111173543.38", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111173543.38"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA", 
              "id": "http://www.grid.ac/institutes/grid.5288.7", 
              "name": [
                "Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Fanning", 
            "givenName": "Shane", 
            "id": "sg:person.01123641753.91", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123641753.91"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.419481.1", 
              "name": [
                "Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zimmermann", 
            "givenName": "J\u00fcrg", 
            "id": "sg:person.07363226302.25", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07363226302.25"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.419481.1", 
              "name": [
                "Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lydon", 
            "givenName": "Nicholas B.", 
            "id": "sg:person.01017774522.42", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017774522.42"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/bjc.1982.75", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008842076", 
              "https://doi.org/10.1038/bjc.1982.75"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/243290a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012018569", 
              "https://doi.org/10.1038/243290a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/306277a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004442914", 
              "https://doi.org/10.1038/306277a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/376785a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022545215", 
              "https://doi.org/10.1038/376785a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/315550a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045340731", 
              "https://doi.org/10.1038/315550a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00124317", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011028642", 
              "https://doi.org/10.1007/bf00124317"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/306239a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007822085", 
              "https://doi.org/10.1038/306239a0"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1996-05", 
        "datePublishedReg": "1996-05-01", 
        "description": "The bcr\u2013abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr\u2013Abl fusion protein. Cellular proliferation and tumor formation by Bcr\u2013Abl\u2013expressing cells were specifically inhibited by this compound. In colony\u2013forming assays of peripheral blood or bone marrow from patients with CML, there was a 92\u201398% decrease in the number of bcr\u2013abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr\u2013abl\u2013positive leukemias.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/nm0596-561", 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2410754", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1113716", 
            "issn": [
              "1078-8956", 
              "1546-170X"
            ], 
            "name": "Nature Medicine", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "5", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "2"
          }
        ], 
        "keywords": [
          "chronic myelogenous leukemia", 
          "BCR-ABL positive cells", 
          "BCR-ABL fusion protein", 
          "tyrosine kinase", 
          "colony-forming assays", 
          "normal colony formation", 
          "peripheral blood", 
          "BCR-ABL oncogene", 
          "myelogenous leukemia", 
          "positive cells", 
          "bone marrow", 
          "positive leukemia", 
          "BCR-ABL", 
          "tumor formation", 
          "colony formation", 
          "cellular proliferation", 
          "selective inhibitor", 
          "patients", 
          "Abl tyrosine kinase", 
          "leukemia", 
          "Abl protein tyrosine kinase", 
          "cells", 
          "protein tyrosine kinases", 
          "fusion protein", 
          "marrow", 
          "disease", 
          "blood", 
          "kinase", 
          "treatment", 
          "inhibitors", 
          "proliferation", 
          "inhibition", 
          "cause", 
          "oncogene", 
          "assays", 
          "effect", 
          "decrease", 
          "protein", 
          "compounds", 
          "number", 
          "colonies", 
          "formation", 
          "growth"
        ], 
        "name": "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells", 
        "pagination": "561-566", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1051513257"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/nm0596-561"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "8616716"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/nm0596-561", 
          "https://app.dimensions.ai/details/publication/pub.1051513257"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T15:47", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_266.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/nm0596-561"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nm0596-561'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nm0596-561'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nm0596-561'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nm0596-561'


     

    This table displays all metadata directly associated to this object as RDF triples.

    258 TRIPLES      21 PREDICATES      94 URIs      79 LITERALS      25 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/nm0596-561 schema:about N186e799058ab44479889bbe898647a24
    2 N2e2514a1cc28412f83d5e58f3703a0a4
    3 N35a34a47069c44e8bbcdc2d85c9dd4da
    4 N3d009ef8643d4dfd96b078c96f1804e2
    5 N4a79044fbe954407a5bac3d7bb29d329
    6 N5fbadf87f4304695aa33dbc96703e100
    7 N61b9ebda1d0a4173ba8525c1721b5ac8
    8 N6eb752845886495287b1767f09adac06
    9 N752d5e32e6e248cdb4878d4471248e75
    10 N75bf5bad290e4ea98b07671ec660fa5a
    11 N8723fb4b394b4667adaf84fedf1f1d4e
    12 N88a513c34b8848858e55677f0c3f3738
    13 Nc2968a3036e545839476d43eedc3b335
    14 Nc48869156d4647b3a08c1695dd208215
    15 Ncea3ff27fbbc41a892c9c41b61469cee
    16 Nec1412333dfc4c02a7c3ed82e08963d8
    17 Nf819980773b34712a89da9cb5b0e2fea
    18 Nfca612402dfb4e6ab9d71f89fb29bdc9
    19 anzsrc-for:11
    20 anzsrc-for:1102
    21 schema:author Na24fd36dfa804b149ddd84b286d4f44a
    22 schema:citation sg:pub.10.1007/bf00124317
    23 sg:pub.10.1038/243290a0
    24 sg:pub.10.1038/306239a0
    25 sg:pub.10.1038/306277a0
    26 sg:pub.10.1038/315550a0
    27 sg:pub.10.1038/376785a0
    28 sg:pub.10.1038/bjc.1982.75
    29 schema:datePublished 1996-05
    30 schema:datePublishedReg 1996-05-01
    31 schema:description The bcr–abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr–Abl fusion protein. Cellular proliferation and tumor formation by Bcr–Abl–expressing cells were specifically inhibited by this compound. In colony–forming assays of peripheral blood or bone marrow from patients with CML, there was a 92–98% decrease in the number of bcr–abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr–abl–positive leukemias.
    32 schema:genre article
    33 schema:isAccessibleForFree false
    34 schema:isPartOf N30ccd47343664833a87226aaca9a4d2f
    35 N6ea6f82d282a41beacce978357c5e5aa
    36 sg:journal.1113716
    37 schema:keywords Abl protein tyrosine kinase
    38 Abl tyrosine kinase
    39 BCR-ABL
    40 BCR-ABL fusion protein
    41 BCR-ABL oncogene
    42 BCR-ABL positive cells
    43 assays
    44 blood
    45 bone marrow
    46 cause
    47 cells
    48 cellular proliferation
    49 chronic myelogenous leukemia
    50 colonies
    51 colony formation
    52 colony-forming assays
    53 compounds
    54 decrease
    55 disease
    56 effect
    57 formation
    58 fusion protein
    59 growth
    60 inhibition
    61 inhibitors
    62 kinase
    63 leukemia
    64 marrow
    65 myelogenous leukemia
    66 normal colony formation
    67 number
    68 oncogene
    69 patients
    70 peripheral blood
    71 positive cells
    72 positive leukemia
    73 proliferation
    74 protein
    75 protein tyrosine kinases
    76 selective inhibitor
    77 treatment
    78 tumor formation
    79 tyrosine kinase
    80 schema:name Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
    81 schema:pagination 561-566
    82 schema:productId N12cd2078a7f742458f10123e93a94657
    83 N7cb0202d06ed4cb1b16848d543ea8964
    84 Nc8291a36f6e44deaa8ddac4c29b7af1e
    85 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051513257
    86 https://doi.org/10.1038/nm0596-561
    87 schema:sdDatePublished 2022-09-02T15:47
    88 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    89 schema:sdPublisher Nb3ced07f6d9a458db8fd8195e4f2af7c
    90 schema:url https://doi.org/10.1038/nm0596-561
    91 sgo:license sg:explorer/license/
    92 sgo:sdDataset articles
    93 rdf:type schema:ScholarlyArticle
    94 N12cd2078a7f742458f10123e93a94657 schema:name doi
    95 schema:value 10.1038/nm0596-561
    96 rdf:type schema:PropertyValue
    97 N186e799058ab44479889bbe898647a24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    98 schema:name Benzamides
    99 rdf:type schema:DefinedTerm
    100 N2e2514a1cc28412f83d5e58f3703a0a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    101 schema:name Pyrimidines
    102 rdf:type schema:DefinedTerm
    103 N30ccd47343664833a87226aaca9a4d2f schema:volumeNumber 2
    104 rdf:type schema:PublicationVolume
    105 N35a34a47069c44e8bbcdc2d85c9dd4da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    106 schema:name Bone Marrow
    107 rdf:type schema:DefinedTerm
    108 N3d009ef8643d4dfd96b078c96f1804e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    109 schema:name Tumor Cells, Cultured
    110 rdf:type schema:DefinedTerm
    111 N4a79044fbe954407a5bac3d7bb29d329 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    112 schema:name Mice
    113 rdf:type schema:DefinedTerm
    114 N5fbadf87f4304695aa33dbc96703e100 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    115 schema:name Protein-Tyrosine Kinases
    116 rdf:type schema:DefinedTerm
    117 N61b9ebda1d0a4173ba8525c1721b5ac8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    118 schema:name Humans
    119 rdf:type schema:DefinedTerm
    120 N6ea6f82d282a41beacce978357c5e5aa schema:issueNumber 5
    121 rdf:type schema:PublicationIssue
    122 N6eb752845886495287b1767f09adac06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Animals
    124 rdf:type schema:DefinedTerm
    125 N752d5e32e6e248cdb4878d4471248e75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Blood Cells
    127 rdf:type schema:DefinedTerm
    128 N75bf5bad290e4ea98b07671ec660fa5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Imatinib Mesylate
    130 rdf:type schema:DefinedTerm
    131 N7cb0202d06ed4cb1b16848d543ea8964 schema:name dimensions_id
    132 schema:value pub.1051513257
    133 rdf:type schema:PropertyValue
    134 N8723fb4b394b4667adaf84fedf1f1d4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    135 schema:name Leukemia, Myelogenous, Chronic, BCR-ABL Positive
    136 rdf:type schema:DefinedTerm
    137 N88a513c34b8848858e55677f0c3f3738 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name Piperazines
    139 rdf:type schema:DefinedTerm
    140 Na24fd36dfa804b149ddd84b286d4f44a rdf:first sg:person.012015172137.23
    141 rdf:rest Nef5c98a7e4b34f1fa099a5e78ceec894
    142 Nb3ced07f6d9a458db8fd8195e4f2af7c schema:name Springer Nature - SN SciGraph project
    143 rdf:type schema:Organization
    144 Nc032aa13de0c41b58e5aa4392914efdb rdf:first sg:person.01123641753.91
    145 rdf:rest Nf13a1757952d42598c04657bf6a9de53
    146 Nc2968a3036e545839476d43eedc3b335 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Fusion Proteins, bcr-abl
    148 rdf:type schema:DefinedTerm
    149 Nc48869156d4647b3a08c1695dd208215 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Stem Cells
    151 rdf:type schema:DefinedTerm
    152 Nc824fef2a0f448ff9557d5d4c528b9c4 rdf:first sg:person.01017774522.42
    153 rdf:rest rdf:nil
    154 Nc8291a36f6e44deaa8ddac4c29b7af1e schema:name pubmed_id
    155 schema:value 8616716
    156 rdf:type schema:PropertyValue
    157 Nc94c6cdd795946089e7a8f1f21ffe58d rdf:first sg:person.01111173543.38
    158 rdf:rest Nc032aa13de0c41b58e5aa4392914efdb
    159 Ncea3ff27fbbc41a892c9c41b61469cee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name Proto-Oncogene Proteins c-abl
    161 rdf:type schema:DefinedTerm
    162 Ne225288965514954acad3d6749396e65 rdf:first sg:person.01060303730.59
    163 rdf:rest Nfc2f0ce0a2d44a64b0208d91e5dab10a
    164 Nec1412333dfc4c02a7c3ed82e08963d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name Dose-Response Relationship, Drug
    166 rdf:type schema:DefinedTerm
    167 Nef5c98a7e4b34f1fa099a5e78ceec894 rdf:first sg:person.0603442270.75
    168 rdf:rest Ne225288965514954acad3d6749396e65
    169 Nf13a1757952d42598c04657bf6a9de53 rdf:first sg:person.07363226302.25
    170 rdf:rest Nc824fef2a0f448ff9557d5d4c528b9c4
    171 Nf819980773b34712a89da9cb5b0e2fea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    172 schema:name Enzyme Inhibitors
    173 rdf:type schema:DefinedTerm
    174 Nfc2f0ce0a2d44a64b0208d91e5dab10a rdf:first sg:person.0717670670.09
    175 rdf:rest Nc94c6cdd795946089e7a8f1f21ffe58d
    176 Nfca612402dfb4e6ab9d71f89fb29bdc9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    177 schema:name Evaluation Studies as Topic
    178 rdf:type schema:DefinedTerm
    179 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    180 schema:name Medical and Health Sciences
    181 rdf:type schema:DefinedTerm
    182 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
    183 schema:name Cardiorespiratory Medicine and Haematology
    184 rdf:type schema:DefinedTerm
    185 sg:grant.2410754 http://pending.schema.org/fundedItem sg:pub.10.1038/nm0596-561
    186 rdf:type schema:MonetaryGrant
    187 sg:journal.1113716 schema:issn 1078-8956
    188 1546-170X
    189 schema:name Nature Medicine
    190 schema:publisher Springer Nature
    191 rdf:type schema:Periodical
    192 sg:person.01017774522.42 schema:affiliation grid-institutes:grid.419481.1
    193 schema:familyName Lydon
    194 schema:givenName Nicholas B.
    195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017774522.42
    196 rdf:type schema:Person
    197 sg:person.01060303730.59 schema:affiliation grid-institutes:grid.419481.1
    198 schema:familyName Buchdunger
    199 schema:givenName Elisabeth
    200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060303730.59
    201 rdf:type schema:Person
    202 sg:person.01111173543.38 schema:affiliation grid-institutes:grid.5288.7
    203 schema:familyName Segal
    204 schema:givenName Gerald M.
    205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111173543.38
    206 rdf:type schema:Person
    207 sg:person.01123641753.91 schema:affiliation grid-institutes:grid.5288.7
    208 schema:familyName Fanning
    209 schema:givenName Shane
    210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123641753.91
    211 rdf:type schema:Person
    212 sg:person.012015172137.23 schema:affiliation grid-institutes:grid.5288.7
    213 schema:familyName Druker
    214 schema:givenName Brian J.
    215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012015172137.23
    216 rdf:type schema:Person
    217 sg:person.0603442270.75 schema:affiliation grid-institutes:grid.5288.7
    218 schema:familyName Tamura
    219 schema:givenName Shu
    220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603442270.75
    221 rdf:type schema:Person
    222 sg:person.0717670670.09 schema:affiliation grid-institutes:grid.5288.7
    223 schema:familyName Ohno
    224 schema:givenName Sayuri
    225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717670670.09
    226 rdf:type schema:Person
    227 sg:person.07363226302.25 schema:affiliation grid-institutes:grid.419481.1
    228 schema:familyName Zimmermann
    229 schema:givenName Jürg
    230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07363226302.25
    231 rdf:type schema:Person
    232 sg:pub.10.1007/bf00124317 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011028642
    233 https://doi.org/10.1007/bf00124317
    234 rdf:type schema:CreativeWork
    235 sg:pub.10.1038/243290a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012018569
    236 https://doi.org/10.1038/243290a0
    237 rdf:type schema:CreativeWork
    238 sg:pub.10.1038/306239a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007822085
    239 https://doi.org/10.1038/306239a0
    240 rdf:type schema:CreativeWork
    241 sg:pub.10.1038/306277a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004442914
    242 https://doi.org/10.1038/306277a0
    243 rdf:type schema:CreativeWork
    244 sg:pub.10.1038/315550a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045340731
    245 https://doi.org/10.1038/315550a0
    246 rdf:type schema:CreativeWork
    247 sg:pub.10.1038/376785a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022545215
    248 https://doi.org/10.1038/376785a0
    249 rdf:type schema:CreativeWork
    250 sg:pub.10.1038/bjc.1982.75 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008842076
    251 https://doi.org/10.1038/bjc.1982.75
    252 rdf:type schema:CreativeWork
    253 grid-institutes:grid.419481.1 schema:alternateName Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland
    254 schema:name Ciba Pharmaceuticals Division, Oncology Research Department, Ciba-Geigy Limited, CH-4002, Basel, Switzerland
    255 rdf:type schema:Organization
    256 grid-institutes:grid.5288.7 schema:alternateName Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA
    257 schema:name Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon, USA
    258 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...